Navigation Links
Michael L. Eskew Elected to Lilly Board of Directors
Date:2/19/2008

Company Also Announces That George M.C. Fisher Will Retire from the Lilly

Board

INDIANAPOLIS, Feb. 19 /PRNewswire-FirstCall/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Michael L. Eskew, former chairman and chief executive officer of United Parcel Service, Inc. (UPS), as a new member, effective February 18, 2008. Eskew will stand for election by the shareholders at the 2008 annual meeting in April.

Eskew, who served as chairman and chief executive officer of UPS from January, 2002 until December, 2007, brings over 35 years of global corporate management experience to the Lilly board.

"We are very pleased to welcome Mike Eskew to the Lilly board," said Sidney Taurel, Lilly chairman and chief executive officer. "His extensive management experiences and his outstanding track record of leadership in a customer-centered organization such as UPS ideally suit him to provide guidance and oversight to Lilly as it transforms itself into a truly patient- centered enterprise. Mike's experience as a board member of other leading American companies will also serve our company well."

Eskew, 58, began his UPS career in 1972 as an industrial engineering manager. After several global assignments with increasing responsibility, he was named corporate vice president for industrial engineering in 1993. In 1996 he became group vice president for engineering, and in 1998, he was elected to the UPS Board of Directors. In 1999, Eskew was named executive vice president and a year later was given the additional title of vice chairman. Eskew serves as a trustee of The UPS Foundation and as the chairman of the Board of Trustees of The Annie E. Casey Foundation. He also serves
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 2Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 4Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2Health News:OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 2Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 3Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 4
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 1Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 2Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 3Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 4Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 5Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 1Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 2Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 3Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 4